Filing Flows › Orchestra BioMed Holdings (OBIO) › Q4 2025
Orchestra BioMed Holdings (OBIO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Orchestra BioMed Holdings (OBIO) reported revenue of $30.9M for the fourth quarter 2025 (Q4 2025), up 122-fold from a year earlier and up 36-fold from the quarter before. Operating margin was 21.8%, net earnings $6.2M (20.2% of revenue).
Orchestra BioMed Holdings, Q4 2025: revenue $30.9M (122× year over year), operating margin 21.8%, net earnings $6.2M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.9M | 36× | 122× |
| Operating profit | $6.8M | — | — |
| Net earnings | $6.2M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $30.9M in Q4 2025, up 12120% year over year and up 3491% from the previous quarter. Partnership revenue was the largest line at 99% of revenue.
Operating profit was $6.8M, a 21.8% margin (up 6613.5 points year over year). Total costs grew 43% against revenue growth of 12120%. The fastest-growing cost line was Research & development (+53%). Net earnings were $6.2M. The effective tax rate was 0.0%.
Operating cash flow was −$2.3M. Non-cash charges added back $82K of depreciation and $2.8M of share-based compensation. Working capital and other items used $11.3M. Capital expenditures of $33K exceeded it, leaving free cash flow of −$2.3M.
Questions
What was Orchestra BioMed Holdings' revenue in the fourth quarter 2025?
Orchestra BioMed Holdings (OBIO) reported revenue of $30.9M for the fourth quarter 2025 (Q4 2025), up 122-fold from a year earlier and up 36-fold from the quarter before.
Was Orchestra BioMed Holdings profitable in the fourth quarter 2025?
Operating profit was $6.8M (21.8% of revenue) and net earnings $6.2M.